| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 1344 6 |
| Ultima descărcare din IBN: 2021-05-25 17:53 |
 SM ISO690:2012RABA, Tatiana. Tratamentul antiviral cu interferon alfa 2b pegilat şi ribavirină în hepatita cronică virală C la copii în Republica Moldova. In: Sănătate Publică, Economie şi Management în Medicină , 2014, nr. 5(56), pp. 73-76. ISSN 1729-8687. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Sănătate Publică, Economie şi Management în Medicină | ||||||
| Numărul 5(56) / 2014 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
| Pag. 73-76 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
The combined antiviral therapy with pegylated interferon alpha 2в and ribavirin is approved in children from 3-year age and teenagers. In compliance with the National Program of the Republic of Moldova in 2007-2011 and 2012-2016 yy 35 children, of age 4-17 years were treated in pediatrics hepatology with pegylated interferon alpha 2в (60 mcg/m2/ week) plus ribavirin (15 mg/kg/day), duration of therapy consisted 24 weeks for genotype 2 or 48 weeks for genotype 1b. Chronic hepatitis C in 35 children was characterized by the minimum clinical signs, low biochemical activity, low virus loading < 600 000 ui/ml in 60% of cases and minimum degree of fibrosis (F0-F2 in 29 of 35 surveyed). 33 patients finished the antiviral treatment, while 2 children discontenued therapy because of the expressed headaches (1) and in connection with immigration overboard of the republic. The received results revealed minimum side effects with achievement of SVR in 73% cases, including: with genotype 1в – 69%, while with genotype 2 and 3а – in 100%. Antiviral therapy in 35 children is seif, but demands an individual approach. |
||||||
| Cuvinte-cheie children, genotype, pegylated interferon, ribavirin, chronic hepatitis viral C, sustained virologic response |
||||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <creators> <creator> <creatorName>Raba, T.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> </creators> <titles> <title xml:lang='ro'>Tratamentul antiviral cu interferon alfa 2b pegilat şi ribavirină în hepatita cronică virală C la copii în Republica Moldova</title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2014</publicationYear> <relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>1729-8687</relatedIdentifier> <subjects> <subject>children</subject> <subject>chronic hepatitis viral C</subject> <subject>genotype</subject> <subject>pegylated interferon</subject> <subject>ribavirin</subject> <subject>sustained virologic response</subject> </subjects> <dates> <date dateType='Issued'>2014-10-31</date> </dates> <resourceType resourceTypeGeneral='Text'>Journal article</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p><em>The combined antiviral therapy with pegylated interferon alpha 2в and ribavirin is approved in children from 3-year age and teenagers. In compliance with the National Program of the Republic of Moldova in 2007-2011 and 2012-2016 yy 35 children, of age 4-17 years were treated in pediatrics hepatology with pegylated interferon alpha 2в (60 mcg/m2/ week) plus ribavirin (15 mg/kg/day), duration of therapy consisted 24 weeks for genotype 2 or 48 weeks for genotype 1b. Chronic hepatitis C in 35 children was characterized by the minimum clinical signs, low biochemical activity, low virus loading < 600 000 ui/ml in 60% of cases and minimum degree of fibrosis (F0-F2 in 29 of 35 surveyed). 33 patients finished the antiviral treatment, while 2 children discontenued therapy because of the expressed headaches (1) and in connection with immigration overboard of the republic. The received results revealed minimum side effects with achievement of SVR in 73% cases, including: with genotype 1в – 69%, while with genotype 2 and 3а – in 100%. Antiviral therapy in 35 children is seif, but demands an individual approach.</em></p></description> <description xml:lang='ru' descriptionType='Abstract'><p><em>Противовирусная комбинированная терапия пегилированным альфа 2в интерфероном и рибавирином апробирована у детей с 3-х летнего возраста. В соответсвии с Национальной Программой Республики Молдова на 2007-2016 г., в отделении детской гепатологии была проведена терапия пегилированным альфа 2в интерфероном 60 (1,5) мсг/неделю в сочетании с рибавирином в дозе 15 мг/</em><em>kg</em><em>/день в течении 24 (генотип 2, 3а) или 48 недель (генотип 1в) у 35 детей в возрасте 4-17 лет, страдающих хроничесим вирусным гепатитом С (генотип 1в – 31, генотип 2 – 1, генотип 3а – 3). Хронический гепатит С у 35 детей характеризовался минимальными клиническими признаками, низкой биохимической активностью, в 60% случаев низкой вирусной нагрузкой < 600 000 </em><em>ui</em><em>/</em><em>ml</em><em> и минимальной степенью фиброза </em><em>F</em><em>0-</em><em>F</em><em>2 у 29 (100%) из 29 обследованных. Полный курс лечения закончили 33 пациента, а 1 пациент отказался продолжать терапию спустя три недели из-за выраженных головных болей и 1 отменил терапию в связи с иммиграцией за пределы республики. Полученные результаты указывают на хорошую приверженность к терапии, минимальные побочные эффекты с достижением УВО в 73% случаях, включительно: при генотипе 1в – 69%, генотипах 2 и 3а – в 100%. Проводимая комбинированная противовирусная терапия у детей пегилированным альфа 2в интерфероном в сочетании с рибавирином </em><em>безопасна, требует индивидуального подхода.</em></p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>
|
|
|
